Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2031

Conditions
Locally Advanced or Metastatic Urothelial Carcinoma
Interventions
DIAGNOSTIC_TEST

Neurological function assessment

Neurological evaluations including neurological examination (NE), nerve conduction study (NCS), quantitative sensory testing (QST), autonomic function testing (AFT), and the Toronto Clinical Neuropathy Score (TCNS) questionnaire. Assessments will be conducted at baseline and every three months until six months after completion of EV treatment.

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER